Suppr超能文献

基于 RNA 的药物变革性突破的框架。

Frameworks for transformational breakthroughs in RNA-based medicines.

机构信息

RNA Accelerator, Pfizer Inc, Cambridge, MA, USA.

Ginkgo Bioworks, Boston, MA, USA.

出版信息

Nat Rev Drug Discov. 2024 Jun;23(6):421-444. doi: 10.1038/s41573-024-00943-2. Epub 2024 May 13.

Abstract

RNA has sparked a revolution in modern medicine, with the potential to transform the way we treat diseases. Recent regulatory approvals, hundreds of new clinical trials, the emergence of CRISPR gene editing, and the effectiveness of mRNA vaccines in dramatic response to the COVID-19 pandemic have converged to create tremendous momentum and expectation. However, challenges with this relatively new class of drugs persist and require specialized knowledge and expertise to overcome. This Review explores shared strategies for developing RNA drug platforms, including layering technologies, addressing common biases and identifying gaps in understanding. It discusses the potential of RNA-based therapeutics to transform medicine, as well as the challenges associated with improving applicability, efficacy and safety profiles. Insights gained from RNA modalities such as antisense oligonucleotides (ASOs) and small interfering RNAs are used to identify important next steps for mRNA and gene editing technologies.

摘要

RNA 在现代医学领域引发了一场革命,有望改变我们治疗疾病的方式。最近的监管批准、数百项新的临床试验、CRISPR 基因编辑的出现,以及 mRNA 疫苗在应对 COVID-19 大流行方面的显著效果,汇聚在一起形成了巨大的动力和期望。然而,这类相对较新的药物仍存在挑战,需要专门的知识和专业技能来克服。本综述探讨了开发 RNA 药物平台的共享策略,包括分层技术、解决常见偏见和识别理解上的差距。它讨论了基于 RNA 的疗法将如何改变医学,以及提高适用性、疗效和安全性的相关挑战。从反义寡核苷酸 (ASO) 和小干扰 RNA 等 RNA 模式中获得的见解被用于确定 mRNA 和基因编辑技术的重要下一步。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验